Abstract
Data from the XTEND-Kids study presented at the 2023 International Society on Thrombosis and Haemostasis Congress showed that once-weekly prophylaxis with efanesoctocog alfa dosed at 50 IU/kg body weight was well tolerated and provided highly effective bleed protection and treatment in children <12 years of age with severe haemophilia A. These findings are consistent with the results of the XTEND-1 trial, which evaluated the efficacy of efanesoctocog alfa in both adults and adolescents.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
